Monday, February 6, 2012

On the Brink of Generic Biotech Drugs, What’s the Cost to Innovation?

May 14, 2010 by biotechconnection.com · Leave a Comment 

In a recently published report, the Federal Trade Commission suggested that the current allotment of a 12- to 14-year regulatory exclusivity period for product innovation to develop products at biotech companies is“too long to promote innovation.”
The same report, published June 4, also indicated that developing generic biotech drugs would help bring down the cost [...]

Generic medication

March 11, 2010 by biotechconnection.com · Leave a Comment 


Conceptually the notion of  a  pill-stop is very modern, but the idea not so contemporary. It is also a very important concept to explore since it is influencing the world markets and the way business is done throughout the globe. The pill-stop is a medicinal store located in the internet and, therefore it is available [...]